MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s patients.
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s patients.
The upcoming two-day event delves into the clinical trial landscape and the strategies employed to increase the region’s attractiveness.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Microbot eyes FDA application for surgical robot after completing pivotal trial
Rivanna starts trial for AI-enabled Accuro XV imaging system
NIH selects Emergex’s T cell vaccine for trials under Project NextGen
Exscientia outline robot and AI use in drug discovery workflow